SCTX insider transaction filings
Scribe Therapeutics, Inc. — 13 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-29. Screen SCTX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 13 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 9 legs across 6 filings by 14 insiders — 4,730,237 shares, $71,344,746 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 26.
- Largest priced transaction: purchase of 2,333,333 shares @ $15.00 ($34,999,995) by Aghazadeh Behzad, filed 2026-07-28.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Aghazadeh Behzad — Director, 10% owner & Avoro Capital Advisors LLC — Director, 10% owner & Avoro Ventures LLC — Director | 2 | 3 legs · 2,391,238 sh · $36,259,761 | — | 1 |
| GORDON CARL L — Director | 2 | 1 leg · 1,000,000 sh · $15,000,000 | — | 3 |
| ORBIMED ADVISORS LLC — Director & OrbiMed Capital GP VIII LLC — Director | 1 | 1 leg · 1,000,000 sh · $15,000,000 | — | 2 |
| AH Bio Fund II, L.P. — 10% owner & AH Equity Partners Bio II, L.L.C. — 10% owner & AH Bio Fund III, L.P. — 10% owner & AH Equity Partners Bio III, L.L.C. — 10% owner & Andreessen Marc L — 10% owner & HOROWITZ BENJAMIN A — 10% owner | 1 | 1 leg · 333,333 sh · $4,999,995 | — | 4 |
| Lucas Svetlana — Chief Business Officer | 1 | 1 leg · 3,000 sh · $45,000 | — | 3 |
| Parrot David — Chief Financial Officer | 1 | 2 legs · 2,666 sh · $39,990 | — | 3 |
| Oakes Benjamin L. — President, CEO, Director | 1 | — | — | 3 |
| Staahl Brett — 10% owner | 1 | — | — | 3 |
| Doudna Jennifer A — 10% owner | 1 | — | — | 2 |
| Bleharski Joshua — Director | 1 | — | — | 1 |
+1 more insider in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Scribe Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-29 | 4 | AH Bio Fund II, L.P. — 10% owner AH Equity Partners Bio II, L.L.C. — 10% owner AH Bio Fund III, L.P. — 10% owner AH Equity Partners Bio III, L.L.C. — 10% owner Andreessen Marc L — 10% owner HOROWITZ BENJAMIN A — 10% owner | Conversion (C): 2,051,742 · Conversion (C): 697,650 · Purchase (P): 333,333 @ $15 · Conversion (C): 12,150,003 (derivative) @ $0 · Conversion (C): 4,131,344 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | GORDON CARL L — Director | Conversion (C): 348,825 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 2,065,672 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VIII LLC — Director | Conversion (C): 348,825 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 2,065,672 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Doudna Jennifer A — 10% owner | Conversion (C): 12,511 · Conversion (C): 74,088 (derivative) | EDGAR |
| 2026-07-28 | 4 | Aghazadeh Behzad — Director, 10% owner Avoro Capital Advisors LLC — Director, 10% owner Avoro Ventures LLC — Director | Purchase (P): 2,333,333 @ $15 · Purchase (P): 50,000 @ $22.31 · Purchase (P): 7,905 @ $18.25 | EDGAR |
| 2026-07-28 | 4 | Staahl Brett — 10% owner | Grant/award (A): 4,755 (derivative) @ $0 · Grant/award (A): 19,385 (derivative) @ $0 · Grant/award (A): 19,385 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Lucas Svetlana — Chief Business Officer | Purchase (P): 3,000 @ $15 · Grant/award (A): 9,547 (derivative) @ $0 · Grant/award (A): 109,426 (derivative) @ $0 · Grant/award (A): 109,426 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | GORDON CARL L — Director | Grant/award (A): 14,725 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Oakes Benjamin L. — President, CEO, Director | Grant/award (A): 12,969 (derivative) @ $0 · Grant/award (A): 264,784 (derivative) @ $0 · Grant/award (A): 429,599 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Watson James Dean — Director | Grant/award (A): 14,725 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Bleharski Joshua — Director | Grant/award (A): 14,725 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Parrot David — Chief Financial Officer | Purchase (P): 1,333 @ $15 · Purchase (P): 1,333 @ $15 · Grant/award (A): 8,909 (derivative) @ $0 · Grant/award (A): 109,426 (derivative) @ $0 · Grant/award (A): 109,426 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Aghazadeh Behzad — Director Avoro Capital Advisors LLC — Director Avoro Ventures LLC — Director | Grant/award (A): 14,725 (derivative) @ $0 | EDGAR |
Recent 8-K events — Scribe Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SCTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →